We are live on ! Find out more
RAPT

RAPT Therapeutics
RAPT

Delisted

RAPT was delisted on the 2nd of March, 2026.

Back to rankings

98 hedge funds and large institutions have $637M invested in RAPT Therapeutics in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,931% more call options, than puts

Call options by funds: $10.8M | Put options by funds: $108K

15% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 33

4% more capital invested

Capital invested by funds: $611M → $637M (+$26.2M)

0.25% more ownership

Funds ownership: 12.14% → 12.39% (+0.25%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

8% less funds holding

Funds holding: 106 → 98 (-8)

47% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 17

Holders
98
Holders Change
-8
Holders Change %
-7.55%
% of All Funds
1.54%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
9
Increased
38
Reduced
33
Closed
17
Calls
$10.8M
Puts
$108K
Net Calls
+$10.7M
Net Calls Change
+$444K

Top Buyers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
+$19.2M
2
DTC
Deep Track Capital
Connecticut
+$8.44M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$7.11M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$3.35M
5
EC
Euclidean Capital
New York
+$2.69M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$6.33M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.98M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.17M
4
RG
Redmile Group
California
-$4.99M
5
N
Nuveen
North Carolina
-$4.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$3.7M +$56.1K +360 +1%
Goldman Sachs
27
Goldman Sachs
New York
$3.51M +$265K +1,702 +8%
FAM
28
Fred Alger Management
New York
$2.96M -$741K -4,756 -19%
Citadel Advisors
29
Citadel Advisors
Florida
$2.81M +$926K +5,948 +46%
Balyasny Asset Management
30
Balyasny Asset Management
Illinois
$2.7M +$844K +5,418 +43%
Rafferty Asset Management
31
Rafferty Asset Management
New York
$2.38M +$309K +1,983 +14%
Millennium Management
32
Millennium Management
New York
$2.2M +$942K +6,047 +70%
Two Sigma Advisers
33
Two Sigma Advisers
New York
$2.03M -$199K -1,275 -9%
Qube Research & Technologies (QRT)
34
Qube Research & Technologies (QRT)
United Kingdom
$2M +$148K +948 +8%
VOYA Investment Management
35
VOYA Investment Management
Georgia
$1.88M +$1.75M +11,208 +818%
UOC
36
UBS O'Connor
Illinois
$1.81M +$92.8K +596 +5%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$1.77M +$31.6K +203 +2%
TD Asset Management
38
TD Asset Management
Ontario, Canada
$1.72M -$33.2K -213 -2%
N
39
Nuveen
North Carolina
$1.6M -$4.69M -30,085 -74%
SSA
40
Schonfeld Strategic Advisors
New York
$1.44M +$1.5M +9,625 New
AG
41
Algert Global
California
$1.41M +$29K +186 +2%
Bank of America
42
Bank of America
North Carolina
$1.37M -$1.28M -8,217 -47%
TOCUITCONY
43
Trustees of Columbia University in the City of New York
New York
$1.37M -$140K -900 -9%
Barclays
44
Barclays
United Kingdom
$1.2M +$281K +1,801 +29%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.17M +$27.6K +177 +2%
Renaissance Technologies
46
Renaissance Technologies
New York
$959K -$1.11M -7,150 -53%
WP
47
Woodline Partners
California
$935K +$974K +6,250 New
JFG
48
Jefferies Financial Group
New York
$911K – – –
UBS Group
49
UBS Group
Switzerland
$886K -$27.4K -176 -3%
Two Sigma Investments
50
Two Sigma Investments
New York
$871K -$334K -2,145 -27%
1
2
3 4 5

RAPT Hedge Fund Activity: Q2 2023 in Review

98 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2023, worth a combined $637M — up 4.3% from $611M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of RAPT and 9 opened new positions — a net loss of 8 holders — while 33 trimmed existing stakes and 38 added.

The largest buyer was Braidwell, opening a new position worth an estimated $19.2M. The largest seller was Cormorant Asset Management, cutting an estimated $6.33M.

  • 98 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2023, down from 106 in Q1 2023.
  • Funds reported $637M of RAPT Therapeutics stock for Q2 2023, up 4.3% quarter-over-quarter.
  • 9 funds opened new RAPT Therapeutics positions in Q2 2023 and 17 closed out, a net change of -8 holders.
  • The largest RAPT Therapeutics buyer in Q2 2023 was Braidwell, an estimated $19.2M added.
  • The largest RAPT Therapeutics seller in Q2 2023 was Cormorant Asset Management, an estimated $6.33M sold.

Based on aggregated 13F filings for Q2 2023.